Accepted Manuscript

Predicting tumour growth and its impact on survival in gemcitabine-treated patients with advanced pancreatic cancer

Maria Garcia-Cremades, Celine Pitou, Philip W. Iversen, Iñaki F. Troconiz

PII: S0928-0987(18)30040-X

DOI: https://doi.org/10.1016/j.ejps.2018.01.033

Reference: PHASCI 4383

To appear in: European Journal of Pharmaceutical Sciences

Received date: 10 October 2017 Revised date: 17 January 2018 Accepted date: 18 January 2018

Please cite this article as: Maria Garcia-Cremades, Celine Pitou, Philip W. Iversen, Iñaki F. Troconiz, Predicting tumour growth and its impact on survival in gemcitabine-treated patients with advanced pancreatic cancer. The address for the corresponding author was captured as affiliation for all authors. Please check if appropriate. Phasci(2017), https://doi.org/10.1016/j.ejps.2018.01.033

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



CCEPTED MANUSCRIPT

TITLE PAGE

Tittle

Predicting tumour growth and its impact on survival in gemcitabine-treated patients

with advanced pancreatic cancer

Author names and affiliations

Maria Garcia-Cremades^{a,b1}, Celine Pitou^c, Philip W. Iversen^d, Iñaki F. Troconiz^{a,b}

^aPharmacometrics and Systems Pharmacology, Department of Pharmacy and Pharmaceutical

Technology, School of Pharmacy, University of Navarra, Pamplona, Spain, mgarcia-

cre@alumni.unav.es; itroconiz@unav.es

bNavarra Institute for Health Research (IdiSNA), University of Navarra, Pamplona, Spain

^cGlobal Pharmacokinetic/Pharmacodynamics and Pharmacometrics, Eli Lilly and Company

Windlesham, Surrey, United Kingdom, pitou_celine@lilly.com

dLilly Research laboratories, Eli Lilly Company, Indianapolis, and Indiana, USA,

iversen_philip_w@lilly.com

Corresponding author

Iñaki F Troconiz

Pharmacometrics & Systems Pharmacology, Department of Pharmacy and Pharmaceutical

Technology, School of Pharmacy, University of Navarra, Pamplona 31008, Spain

Telephone: +34 948 42 56 00 ext. 806507; Fax: +34 948 42 57 40

e-mail: itroconiz@unav.es

¹Present address: Dept. Bioengineering, UC San Francisco, San Francisco, California. USA

1

Download English Version:

https://daneshyari.com/en/article/8511705

Download Persian Version:

https://daneshyari.com/article/8511705

<u>Daneshyari.com</u>